Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $(0.99) by 207.65 percent. This is a 242.67 percent increase over losses of $(0.75) per share from the same period last year.